All In Biotech

Drug Trial Radar · NCT06385678

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

A Phase IB/II Clinical Study on the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Medication in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Actual

Start

Jul 5, 2024

Primary completion

Dec 2025

Study completion Aug 2026

Sponsor

Sponsor type
Industry
First posted
Apr 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.

Conditions

  • Advanced KRAS G12D Mutant Solid Tumors

Interventions

  • HRS-4642Drug

    administrated per dose level in which the patients are assigned

  • AdebrelimabDrug

    administrated per dose level in which the patients are assigned

  • SHR-9839Drug

    administrated per dose level in which the patients are assigned

  • Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for InjectionDrug

    administered as prescribed by the investigator.

  • Cetuximab Solution for InfusionDrug

    administrated per dose level in which the patients are assigned

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase IB: Safety endpoints: adverse events (AEs).Time frame: 24 months
  2. Phase IB: Maximum tolerated dose (MTD)Time frame: From Day 1 to Day 21
  3. Phase IB:Recommended phase 2 dose (RP2D)Time frame: 24 months
  4. Phase II: Overall response rate (ORR).Time frame: 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.